SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA completes inspection at Kopran's arm facility

25 Jan 2019 Evaluate

Kopran’s wholly owned subsidiary - Kopran Research Laboratories has been inspected by the United States Food and Drug Administration (USFDA) starting from January 21 till January 25, 20 l 9. The Inspection has been completed without issuance of any observation.

This will facilitate commencement of supplies of APIs to the US market once DMF's are filed and approved. The company has filed the DMF of Atenolol which is already reviewed and active.

Kopran is engaged in pharmaceutical business. The company’s business units include Finished Dosage Forms, Active Pharmaceutical Ingredients, Research and Development, and Consumer Healthcare.

Kopran Share Price

155.40 -4.20 (-2.63%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×